Short-acting beta2-agonists for stable chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Sestini, Piersante ^a   Renzoni, E ^b   Robinson, Stewart ^c   Poole, Phillippa ^d   Ram, Felix S F ^e  

^a UNIVERSITY OF SIENA   (Italy)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e MASSEY UNIVERSITY   (New Zealand)

Author keywords

Administration, inhalation; Adrenergic beta agonists pharmacokinetics; * therapeutic use ; Adult; Albuterol therapeutic use ; Bronchodilator agents *therapeutic use ; Humans; Lung diseases, obstructive *drug therapy ; Randomized controlled trials astopic; Terbutaline therapeutic use

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BITOLTEROL; FENOTEROL; IPRATROPIUM BROMIDE; ORCIPRENALINE; PIRBUTEROL; PLACEBO; REPROTEROL; SALBUTAMOL; SHORT ACTING DRUG; TERBUTALINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; DISEASE EXACERBATION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FORCED EXPIRATORY VOLUME; HUMAN; QUALITY OF LIFE; REVIEW; SPIROMETRY; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

EID: 77950119351     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001495     Document Type: Review

References (73)

1. Dullinger 1986 {published data only} Dullinger D, Kronenberg R, Niewoehner DE. Efficacy of inhaled metaproterenol and orally-administered theophylline in patients with chronic airflow obstruction. Chest 1986;89(2):171-3.
2. Guyatt 1987 {published data only} Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor W, et al.Bronchilators in chronic air-flow limitation. American Review of Respiratory Disease 1987;135:1069-74.
3. Guyatt 1988 {published data only} Guyatt GH, Townsend M, Nogradi S, Pugsley SO, Keller JL, Newhouse MT. Acute responses to bronchodilator - an imperfect guide for bronchodilator therapy in chronic airflow limitation. Archives of Internal Medicine 1988;148:1949-52.
4. Guyatt 1989 {published data only} Guyatt GH, Townsend M, Keller JL, Singer J. Should study subjects see their previous responses: data from a randomized control trial. Journal of Clinical Epidemiology 1989;42(9):913-20.
5. Hansen 1990 {published data only} Hansen NC, May O. Domiciliary nebulised terbutaline in severe chronic airways obstruction. European Respiratory Journal 1990;3:463-4.
6. Jaeschke 1991 {published data only} Jaeschke R, Guyatt GH, Singer J, Keller J, Newhouse MT. Mechanism of bronchodilator effect in chronic airflow limitation. Canadian Medical Association Journal 1991;144(1):35-9.
7. Klock 1975 {published data only} Klock LE, Miller TD, Morris AH,Watanabe S, Dickman M. A comparative study of atropine sulphate and isoproterenol hydrochloride in chronic bronchitis. American Review of Respiratory Disease 1975;112:371-6.
8. Light 1975 {published data only} Light RW, Summer WR, Luchsinger PC. Response of patients with chronic obstructive lung disease to the regular administration of nebulized isoproterenol. Chest 1975;67(6):634-9.
9. Shah 1983 {published data only} Shah SS, Johnsonton D, Woodcock AA, Johnson M, Geddes DM. Breathlessness and exercise tolerance in chronic airflow obstruction: 2-hourly versus 4-hourly salbutamol by inhalation. Current Medical Research and Opinion 1983;8(5):345-9.
10. Silins 1985 {published data only} Silins RA, Marlin GE. Evaluation of domiciliary treatment with terbutaline by wet nebulisation in patients with chronic bronchitis and emphysema. Australian and New Zealand Journal of Medicine 1985;15:230-4.
11. Tandon 1990 {published data only} Tandon MK, Kailis SG. Bronchodilator treatment for partially reversible chronic obstructive airways disease. Thorax 1991;46:248-51.
12. Taylor 1985 {published data only} Taylor DR, Buick B, Kinney C, Lowry RC, McDevitt DG. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. American Review of Respiratory Disease 1985;131:747- 51.
13. Wilson 1980 {published data only} Wilson RS, Connellan SJ. Domicillary nebulised salbutamol solution in severe chronic airway obstruction. Thorax 1980;35:873-6.
14. Aalto 1992 {published data only} Aalto E, Havu M, Kotaniemi J, Nieminen P, Svahn T, SvenssonM, et al.Comparison of terbutaline turbuhaler and albuterol chlorofluorocarbon (CFC) inhaler in middle-aged and elderly patients with obstructive lung disease. Annals of Allergy 1992;69:33-6.
15. Allen 1988 {published data only} Allen MB, Pugh J, Wilson RS. Nebuhaler or nebulizer for high dose bronchodilator therapy in chronic bronchitis: a comparison. British Journal of Diseases of the Chest 1988;82:368-73.
16. Aquilina 1986 {published data only} Aquilina R, Bergero F, Noceti P, Mirabelli S, Luciani G. Protective effect of Dovent versus salbutamol in long-term treatment. Respiration 1986;50(Suppl 2):240-4.
17. Backman 1985 {published data only} Backman R, Hellstrom PE. Fenoterol and ipratropium bromide in respiratory treatment of patients with chronic bronchitis. Current Therapeutic Research 1985;38(1):135- 40.
18. Blosser 1995 {published data only} Blosser SA, Maxwell SL, Reeves-Hoche MK, Localio AR, Zwillich CW. Is an anticholinergic agent superior to a beta-2 agonist in improving dyspnea and exercise limitation in COPD?. Chest 1995;108:730-35.
19. Bossert 1989 {published data only} Bossert von J, Trager E. Additive effects of combination treatment of salbutamol and slow-release theophylline as compared with salbutamol alone [Theophylline plus Salbutamol bei chronischer bronchialobstruction]. Fortschritte der Medizin 1989;107(11):255-8/67-72.
20. Christensen 1991(a) {published data only} Christensen EF, Dahl R. Treatment of chronic bronchitis with terbutaline inhaled from a cone spacer with or without positive expiratory pressure. Lung 1991;169:325-33.
21. Christensen 1991(b) {published data only} Christensen EF, Norregaard O, Dahl R. Nebulized terbutaline and positive expiratory pressure in chronic obstructive pulmonary disease. Pneumologie 1991;45:105-9.
22. Combivent 1994 {published data only} Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994;105:1411-9.
23. Combivent 1997 {published data only} Combivent Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997;112:1514-21.
24. Connellan 1979 {published data only} Connellan SJ, Wilson RSE. The use of domiciliary nebulized salbutamol in the treatment of severe emphysema. British Journal of Clinical Practice 1979:135-6.
25. Connolly 1987 {published data only} Connolly CK, Chan NS. Salbutamol and ipratropium in partially reversible airway obstruction. Chest 1987;81:55-61.
26. Cook 2001 {published data only} Cook D, Guyatt G, Wong E, Goldstein R, Bedard M, Austin P, et al.Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 2001;163(1):85-90.
27. Emirgil 1969 {published data only} Emirgil C, Sobol BJ, Norman J, Moskowitz E, Goyal P, Wadhwani B, et al.A study of the long-term effect of therapy in chronic obstructive pulmonary disease. American Journal of Medicine 1969;47:367-77.
28. Grassi 1986 {published data only} Grassi V, Bruni B, Peccini F, Tantucci C, Todisco T. Acute on chronic comparative effects of a combination of fenoterolipratropium bromide and terbutaline in patients with chronic obstructive lung diseases. Respiration 1986;50(Suppl 2):226-31.
29. Hansen 1994 {published data only} Hansen NCG, Evald T, Ibsen TB. Terbutaline inhalations by the turbuhaler as replacement for domiciliary nebulizer therapy in severe chronic obstructive pulmonary disease. Respiratory Medicine 1994;88:267-71.
30. Ibsen 1990 {published data only} Ibsen TB, Svedsen UG and Turbuhaler Multicentergruppen. The significance of incorrect spray technique on the consumption of terbutaline in patients with chronic obstructive lung disease (article in Danish) [Betydningen af fejlagtig sprayteknik pa terbutalinforbruget hos patienter med kronisk obstructiv lungesyngdom]. Ugeskrift for Laeger 1990;152(19):1375-8.
31. Jaeschke 1994 {published data only} Jaeschke R, Guyatt GH, Willan A, Cook D, Harper S, Morris J, et al.Effect of increasing doses of beta agonists on spirometric parameters, exercise capacity, and quality of life in patients with chronic airway limitation. Thorax 1994;49:479-84.
32. Jenkins 1987 {published data only} Jenkins SC, Heaton RW, Fulton TJ, Moxam J. Comparison of domiciliary nebulized salbutamol and salbutamol from a metereddose inhaler in stable chronic airflow limitation. Chest 1987;91(6):804-7.
33. Klein 1964 {published data only} Klein RC, Salvaggio JE, Kundur VG. The response of patients with "idiopatic" obstructive pulmonary disease and "allergic" obstructive bronchitis to prednisone. Annals of Internal Medicine 1964;71(4):711-8.
34. Lighbody 1978 {published data only} Lightbody IM, Ingram CG, Legge JS, Johnston RN. Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis. British Journal of Diseases of the Chest 1978;72:181-6.
35. Lipworth 1990 {published data only} Lipworth BJ, Clark RA, Dhillon DP, Mcdevitt DG. Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on beta-adrenoceptor responsiveness in patients with chronic obstructive pulmonary disease. American Review of Respiratory Diseases 1990;142:338-42.
36. McGivern 1984 {published data only} McGivern DV, Ward M, Revill S, Sechiari A, Macfarlane J, Davies D. Home nebulizers in severe chronic asthma. British Journal of Diseases of the Chest 1984;78:376-82.
37. McIntosh 1983 {published data only} McIntosh D. A trial of fenoterol for nocturnal bronchospasm. The Practitioner 1983;227:1757-64.
38. Mestitz 1989 {published data only} Mestitz H, Copland JM, McDonald CF. Comparison of outpatient nebulized vs metered dose inhaler terbutaline in chronic airflow obstruction. Chest 1989;96(6):1237- 40.
39. Morrison 1992 {published data only} Morrison JGJ, Jones PC, Muers MF. Assessing physiological benefit from domiciliary nebulized bronchodilators in severe airflow limitation. European Respiratory Journal 1992;5:424-29.
40. Nishimura 1995 {published data only} Nishimura K, Koyama H, Ikeda A, Sugiura N, Kawakatsu K, Izumi T. The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD. Chest 1995;107:718-23.
41. O'Driscoll 1990 {published data only} O'Driscoll BR, Kay EA, Taylor RJ, Bernstein A. Home nebulizers: can optimal therapy be predicted by laboratory studies?. Respiratory Medicine 1990;84:471-7.
42. O'Driscoll 1992 {published data only} O'Driscoll BR, Kay EA, Taylor RJ, Weatherby H, Chetty MCP, Bernstein A. A long-term prospective assessment of home nebulizer treatment. Respiratory Medicine 1992;317:317-25.
43. O'Driscoll 1996 {published data only} O'Driscoll BR, Bernstein A. A long-term study of symptoms, spirometry and survival amongst home nebulizer users. Respiratory Medicine 1996;90:561-6.
44. Pedersen 1979 {published data only} Petersen BN, Weeke E. Ipratropium or terbutaline [Ipratropium or terbutaline. En sammenlignende undersegreise hos 19 patienter med kronisk obstruktive lungelideiser]. Ugeskrift for Laeger 1979;141(36):2439-42.
45. Perri 1985 {published data only} Perri G, Giovannini M, Spada E. Salbutamol plus bechlomethsone dipropionate (Ventolin Flogo) vs. fenoterol (Dosberotec) in chronic obstructive lung disease therapeutic strategy: a 4 week clinical trial. International Journal of Clinical Pharmacology Therapeutics & Toxicology 1985;23(5):274-8.
46. Petro 1981 {published data only} Petro W, Nakhosten JA, Konietzko N. Bronchodilator effect of a combination of a beta-adrenergic agonist and a cholinergic antagonist [Broncholyse unter kombinierter Anwendung von beta-adrenergen Agonisten und cholinergen Antagonisten]. Praxis und Klinik der Pneumologie 1981;35:779-82.
47. Petty 1984 {published data only} Petty TL, Scoggin CH, Rollins DR, Repsher LH. Bitolterol compared to isoproterenol in advanced chronic obstructive pulmonary disease. Chest 1984;86(3):404-8.
48. Stalenheim 1994 {published data only} Stalenheim G, Wegener T, Grettve L, Lundback B, Melander B, Osterman K, et al.Efficacy and tolerance of a 12-week treatment with inhaled formoterol in patients with reversible obstructive lung disease. Respiration 1994;61:305-9.
49. Stiksa 1984 {published data only} Stiksa G, Nemcek K, Melin S. Effects of inhaled N-acetylcysteine in combination with terbutaline. European Journal of Respiratory Diseases 1984;65:278-82.
50. Tanser 1982 {published data only} Tanser AR. Maintenance of bronchodilation in chronic reversible airways obstruction. Comparison between choline theophyllinate and salbutamol. The Practitioner 1982;226:569-71.
51. Teale 1991 {published data only} Teale C, Morrison JFJ, Jones PC, Muers MF. Reversibility tests in chronic obstructive airways disease: their predictive value with reference to benefit from domiciliary nebulizer therapy. Respiratory Medicine 1991;85:251-84.
52. van Schayck 1991 {published data only} van Schayck CP, Dompeling E, van Herwaarden CLA, Folgering H, Verbeek ALM, van der Hoogen HJM, et al.Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomized controlled study. British Medical Journal 1991;303:1426-31.
53. van Schayck 1992 {published data only} van Schayeck CP, Rutten-van Molken MPMH, van Doorslaer EKA, Folgering H, vanWeel C. Two-year bronchodilator treatment in patients with mild airflow obstruction. Contradictory effects on lung function and quality of life. Chest 1992;102:1384-91.
54. van Schayck 1994 {published data only} van Schayck CP, Folgering H, den Otter JJ, Tirimanna P, vanWeel C. [Maskeert continu gebruik van bronchusverwijders de progressie van cara?]. Tijdschrift Voor Geneeskunde 1994;50:787-94.
55. van Schayck 1995 {published data only} van Schayck CP, Dompeling E, van Herwaarden CL, Folgering H, van der Broek PJ, vanWeel C. Continuous and on demand use of bronchodilators in patients with non-steroid dependent asthma and chronic bronchitis: four-year follow-up randomized control study. British Journal of Clinical Practice 1995;45:239-44.
56. Ydreborg 1997 {published data only} Ydreborg S O, Svedmyr N, Thiringer G. Comparison of rimiterol and terbutaline, given by aerosol, in a long-term study. Scandinivian Journal of Respiratory Diseases 1997;58:117-24.
57. Appleton 2000 Appleton S, Smith B, Veale A, Bara A. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2000, Issue 2. [MEDLINE: 10796594]
58. Bellamy 1981 Bellamy D, Hutchinson DCF. The effects of salbutamol aerosol on lung function in patients with pulmonary emphysema. British Journal of Diseases of the Chest 1981;75:190-6.
59. Cleophas 1993 Cleophas TJ. Carry-over biases in clinical pharmacology. European Journal of Clinical Chemistry & Clinical Biochemistry 1993;31(12):803-9.
60. Cleophas 1996a Cleophas TJ. Clinical trials: relevance of correlation between treatment responses. European Journal of Clinical Pharmacology 1996;50(1-2):1-6.
61. Cleophas 1996b Cleophas TJ. Crossover trials are only useful when there is a positive correlation between the response to different treatment modalities. British Journal of Clinical Pharmacology 1996;41(3): 235-9.
62. Connellan 1982 Connellan SJ, Gough SE. The effects of nebulized salbutamol on lung function and exercise tolerance in patients with severe airway obstruction. British Journal of Diseases of the Chest 1982;76:135-42.
63. Formgren 1994 Formgren H, Sjokvist A, Stahl E, Wiren JE. Terbutaline in COPD comparison between turbuhaler and chloroflurocarbon (CFC) inhaler. Lung 1994;172:271-80.
64. Guyatt 1986 Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R, Pugsley S. Determining optimal therapy- Randomized trials in individual patients. New England Journal of Medicine 1986;314:889-92.
65. Guyatt 1987a Guyatt GH, Berman LB, TownsendM, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-8.
66. Ikeda 1999 Ikeda A, Nishimura K, Koyama H, Tsukino M, Hajiro T, Mishima M, et al.Comparison of the bronchodilator effects of salbutamol delivered via a metered-dose inhaler with spacer, a dry-powder inhaler, and a jet nebulizer in patients with chronic obstructive pulmonary disease. Respiration 1999;66:119-23.
67. Iversen 1999 Iversen ET, Sorensen T, Heckscher T, Jensen JI. Effect of terbutaline on exercise capacity and pulmonary function in patients with chronic obstructive pulmonary disease. Lung 1999;177:263-71.
68. Murariu 1998 Murariu C, Ghezzo H, Milic-Emili J, Gautier H. Exercise limitation in obstructive lung disease. Chest 1998;114:965-8.
69. Mutterlein 1990 Mutterlein VR, Schmidt G, Fleischer W, Freund E. A new inhalation system for bronchodilation. A study of the acceptance of the Ingelheim M inhalator by chronic obstructive pulmonary disease patients [Ein neues inhalationssystem zur bronchodilation]. Fortscritte der Therapie (Pneumologie) 1990;108(11):225-8/61-6.
70. Noseda 1995 Noseda A, Schmerber J, Prigogine T, deMaertelaer V, Yernault J-C. Perception of dyspnea during acute changes in lung function in patients with either asthma or COPD. Respiratory Medicine 1995;89:477-85.
71. Poole 1998 Poole PJ, Brodie SM, Stewart JM, Black PN. The effects of nebulised isotonic saline and terbutaline on breathlessness in severe chronic obstructive pulmonary disease. Australia New Zealand Journal of Medicine 1998;28(3):322-6.
72. Redelmeier 1997 Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. American Journal of Respiratory and Critical Care Medicine 1997;155(4):1278-82.
73. Tantucci 1999 Tantucci C, Grassi V. Flow limitation: an overview. Monaldi Archives of Chest Diseases 1999;54(4):353-7.